In a patient with recurrent urinary tract infections who is currently receiving ertapenem (1 g intravenous daily) based on susceptibility testing, with no kidney stones on computed tomography and a pending post‑void residual measurement, what is the optimal management plan?

Optimal Management Plan for Recurrent UTIs on Ertapenem

Complete the current ertapenem course (7-14 days total based on clinical response), await the post-void residual result to identify incomplete bladder emptying as a correctable cause, and then transition to long-term non-antimicrobial prophylaxis with methenamine hippurate 1g twice daily or cranberry supplements (≥36mg PACs) to prevent future recurrences 1, 2.

Immediate Management: Complete Current Treatment

• Continue ertapenem 1g IV daily until clinical improvement and symptom resolution 3
• Treatment duration should be 7-14 days for complicated UTI, depending on severity and clinical response 2
• Do NOT perform post-treatment urine culture if the patient becomes asymptomatic—this is explicitly not recommended 1, 2
• Monitor for ertapenem neurotoxicity, particularly given the recurrent nature requiring repeated courses (watch for confusion, seizures, myoclonus) 4, 5

Critical Pending Investigation: Post-Void Residual

The pending post-void residual (PVR) is essential because:

• Elevated PVR (>50-100mL) indicates incomplete bladder emptying, a correctable mechanical factor driving recurrent UTIs 2
• This represents a modifiable risk factor that, if addressed, can break the cycle of recurrence
• If PVR is elevated, consider urological evaluation for bladder outlet obstruction, neurogenic bladder, or pelvic organ prolapse

Long-Term Prevention Strategy: Non-Antimicrobial First

After completing ertapenem, prioritize non-antimicrobial prophylaxis to avoid antibiotic resistance and ecological harm 1, 2:

First-Line Non-Antimicrobial Options:

1. Methenamine hippurate 1g twice daily (Strong recommendation) 1, 2

   • Recent 2024 RCT demonstrated non-inferiority to daily antibiotics
   • Reduced UTI episodes by 0.49 per person-year
   • No vitamin C supplementation needed (does not enhance efficacy) 1

2. Cranberry supplements standardized to ≥36mg PACs 1, 2

   • 2024 meta-analysis showed 54% reduction in UTI rates
   • Reduced antibiotic use by 50%
   • Minimal side effects

3. Increase water intake to >1.5L/day if baseline intake is low 1, 2

   • Reduced mean UTI episodes from 3.2 to 1.7 over 12 months
   • Increased interval between episodes from 84 to 143 days

Only If Non-Antimicrobial Measures Fail:

1. Continuous antimicrobial prophylaxis with nitrofurantoin 50-100mg daily, cephalexin 250mg daily, or trimethoprim 100mg daily 1, 2
   • Reserve this for treatment failures to minimize resistance

Additional Workup Considerations

Given recurrent UTIs despite negative CT for stones:

• Do NOT perform extensive routine workup (cystoscopy, full abdominal ultrasound) if patient is <40 years old without risk factors 2
• Consider workup if: age >40, male gender, persistent hematuria, or other concerning features
• Evaluate for diabetes, immunosuppression, or anatomic abnormalities if not already done 2

Common Pitfalls to Avoid

1. Do not continue carbapenem prophylaxis long-term—this promotes multidrug resistance and is not guideline-supported
2. Do not obtain "test of cure" cultures in asymptomatic patients—this leads to unnecessary treatment of asymptomatic bacteriuria 1, 2
3. Do not ignore the PVR result—elevated residual is a treatable cause that antibiotics alone cannot fix
4. Do not skip non-antimicrobial prophylaxis—jumping straight to antibiotic prophylaxis increases resistance risk 1, 2

Algorithmic Approach Summary

1. Now: Complete ertapenem course (7-14 days) → Monitor for clinical improvement
2. Next: Review PVR result → If elevated, pursue urological correction
3. Then: Initiate methenamine hippurate 1g BID OR cranberry ≥36mg PACs
4. Add: Increase fluid intake if baseline <1.5L/day
5. Only if above fails: Consider continuous antibiotic prophylaxis with nitrofurantoin/cephalexin/trimethoprim

This stepwise approach addresses the acute infection with appropriate antimicrobial therapy while establishing sustainable prevention that minimizes antibiotic exposure and resistance development 1, 2.